Clinical Trials from The University of Texas Health Science Center at Houston

Studies available for: Dermatology

See a study that interests you? Contact that study's coordinator for more information on how to participate.

Study Information:

Study Title:APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic (Tacrolimus) Ointment for the Treatment of Atopic Dermatitis

Study Location:Houston, TX

Facility Name:Houston Medical Center Building

Study Description:This study will follow the health of subjects who have used Protopic (a treatment for ezcema) when they were between the ages of 2 and 16 years. Subjects will be followed for 10 years. Every 6 months, they will receive a questionnaire in the mail. Subjects will see their pediatrician every year and will see a dermatologist every 2 years.

HSC Number:HSC-MS-05-0557

Funding Agency/Source:Astellis Pharmaceuticals (formerly Fujisawa Healthcare)

Subject Information:

Subject Age Range:Subjects who used Protopic between the ages of 2 and 16 years.

Inclusion/Exclusion Criteria:Subjects with eczema who have used Protopic for at least 6 weeks who began treatment when they were from ages 2-16 will be included.

Study Coordinator(s) Information:

Name:Maria D. Lopez

E-mail:maria.d.lopez@uth.tmc.edu

Phone Number:713-500-8266

Principal Investigator Information:

Name:Adelaide A. Hebert, MD

CV:Information on the Principal Investigator

Study Information:

Study Title:Ceramide containing multivesicular emulsion application as a skin hydration treatment for feet of subjects with non insulin-dependent diabetes mellitus

Study Location:Houston, TX

Facility Name:Houston Main Center

Study Description:A study to determine if CeraVe cream is able to prevent transepidermal water loss and foot dryness in people with non insulin dependent diabetes.

HSC Number:HSC-MS-09-0233

Funding Agency/Source:NIH

Subject Information:

Subject Age Range:18+

Inclusion/Exclusion Criteria:Inclusion: 1) >18 years of age 2) non insulin-dependent diabetes 3) moderate to severe xerosis of both feet [a score of at least 4 on a scale of 0 (normal) to 8 (deep fissuring)] 4) capable of understanding and signing consent form Exclusion: 1) history of ichthyosis vulgaris 2) known hypersensitivity to the topical product used in the study 3) previous use of high potency steroids (class I and II) in past 2 week 4) presence of acute skin disease or infection, such as vascultitis or cellulitis 5) presence of foot ulcer 6) evidence of gangrene

Study Coordinator(s) Information:

Name:Maria Lopez

E-mail:maria.d.lopez@uth.tmc.edu

Phone Number:713-500-8266

Name:Laura Lester, MD

E-mail:laura.j.lester@uth.tmc.edy

Phone Number:713-500-8266

Principal Investigator Information:

Name:Adelaide Hebert

Study Information:

Study Title:A randomized, double-blind, double dummy, comparative, multicenter study to assess the safety and efficacy of topical Retapamulin ointment 1%, versus oral Linezolid in the treatment of secondarily-infected traumatic lesions and impetigo due to Methicillin-resistant Staphylococcus aureus.

Study Location:Houston, TX

Facility Name:Houston Medical Center Building

Study Description:This study will evaluate a topical medication to treat minor skin infections. There will be 5 visits over 19 days. Compensation is provided for parking and time. There is no cost to study subjects.

HSC Number:HSC-MS-09-0344

Funding Agency/Source:GlaxoSmithKline

Subject Information:

Subject Age Range:6 months and older

Inclusion/Exclusion Criteria:Subjects must have a minor skin infection due to trauma or impetigo. Subjects must not: 1) have an allergy to the study medication 2) have phenylketonuria or hypersensitivity to aspartame 3) have an infection from an animal or human bite or a puncture wound 4) have an abscess 5) have a chronic ulcerative lesion 6) have an underlying skin disease that is infected 7) have signs of systemic infection 8) have an infection that the physician deems unsuitable to treatment with topical therapy 9) have an infection needing surgical intervention 10) take serotonergic or adrenergic medications 11) have taken systemic antibiotics or steroids or used topical theraputic agents on the wound within the last 24 hours 12) have a history of pseudomembranous

Study Coordinator(s) Information:

Name:Maria Lopez

E-mail:Maria.D.Lopez@uth.tmc.edu

Phone Number:713-500-8266

Principal Investigator Information:

Name:Adelaide A. Hebert, M.D.

Study Information:

Study Title:A Phase II Randomized, Double Blind, Placebo Controlled Dose Finding Study

Study Location:Houston, TX

Facility Name:Houston Medical Center Building

Study Description:This study is evaluating a topical medication to treat venous leg ulcers. Subjects will have up to 17 visits over 17 weeks. Compensation is provided for time and parking. There is no cost to the subjects.

HSC Number:HSC-MS-09-0144

Funding Agency/Source:Healthpoint, Ltd.

Subject Information:

Subject Age Range:18 years and older

Inclusion/Exclusion Criteria:Subjects must have a leg ulcer between the knee and ankle that is due to venous disease that has been present for at least 6 weeks, but no longer than 24 months. Subjects must be willing and able to tolerate compression therapy. Subjects must not be pregnant, have Hashimoto's thyroiditis or Grave's disease.

Study Coordinator(s) Information:

Name:Maria Lopez

E-mail:Maria.D.Lopez@uth.tmc.edu

Phone Number:713-500-8266

Principal Investigator Information:

Name:Adelaide A. Hebert, M.D.

Study Information:

Study Title:Safety and efficacy of TACLONEX ointment in adolescent patients (aged 12 to 17 years) with psoriasis vulgaris

Study Location:Houston, TX

Facility Name:Houston Medical Center Building

Study Description:This study is evaluating a topical medication called Taclonex for the treatment of psoriasis in adolescent patients aged 12 to 17 years. There are 5 visits over a 6 to 10 week period. Compensation is provided for time and parking. There is no cost to the subjects.

HSC Number:HSC-MS-09-0120

Funding Agency/Source:Leo Pharmaceutical Products Ltd.

Subject Information:

Subject Age Range:12-17

Inclusion/Exclusion Criteria:Subjects must have psoriasis. Subjects must not 1) be pregnant 2) have severe kidney or liver disease 3) have diabetes mellitus 4) have Cushing's or Addison's disease.

Study Coordinator(s) Information:

Name:Maria Lopez

E-mail:Maria.D.Lopez@uth.tmc.edu

Phone Number:713-500-8266

Principal Investigator Information:

Name:Adelaide A. Hebert, M.D.

Study Information:

Study Title:A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Clinical Study to Evaluate the Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients with Moderate to Severe Atopic Dermatitis

Study Location:Houston, TX

Facility Name:Houston Medical Center Building

Study Description:This is a study evaluating a topical medication for adults with atopic dermatitis. There are 3 visits over 15 days. Compensation is provided for time and parking. There is no cost to subjects.

HSC Number:HSC-MS-08-0394

Funding Agency/Source:Taro Pharmaceuticals USA, Inc.

Subject Information:

Subject Age Range:18 and older

Inclusion/Exclusion Criteria:Subjects must have moderate to severe atopic dermatitis. Subjects must not be pregnant or lactating.

Study Coordinator(s) Information:

Name:Maria Lopez

E-mail:Maria.D.Lopez@uth.tmc.edu

Phone Number:713-500-8266

Principal Investigator Information:

Name:Adelaide A. Hebert, M.D.